Memantine Hydrochloride And Donepezil Hydrochloride Capsule, Extended Release
Product Images NDC 69680-183

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride And Donepezil Hydrochloride (NDC 69680-183). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Vitruvias Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel – 14/10 mg Bottle (Label 14mg)

This is a medication label for a capsule containing 14 mg of memantine HCl extended release and 10 mg of donepezil HCl. The usual dosage is one capsule per day. The medication should be stored at 20°C to 25°C and dispensed in a light-resistant container. It is manufactured by Xiamen LP Pharmaceutical Co., Ltd. in China and distributed by Vitruvias Therapeutics in the USA. The packaging includes information like lot number, expiration date, and package insert details.*

FDA Label Image

Principal Display Panel – 28/10 mg Bottle (Label 28mg)

FDA Label Image

Memantine Hydrochloride Structural Formula (Memantine And Donepezil Hydrochlorides 1)

FDA Label Image

Figure 8 (Memantine And Donepezil Hydrochlorides 10)

FDA Label Image

Donepezil Hydrochloride Structural Formula (Memantine And Donepezil Hydrochlorides 2)

FDA Label Image

Figure 1 (Memantine And Donepezil Hydrochlorides 3)

FDA Label Image

Figure 2 (Memantine And Donepezil Hydrochlorides 4)

FDA Label Image

Figure 3 (Memantine And Donepezil Hydrochlorides 5)

FDA Label Image

Figure 4 (Memantine And Donepezil Hydrochlorides 6)

FDA Label Image

Figure 5 (Memantine And Donepezil Hydrochlorides 7)

This text describes a study evaluating the clinical improvement and decline over 3 months of drug treatment with donepezil hydrochloride at a dosage of 10 mg/day compared to placebo. The results display certain percentage improvements and declines over the specified time frame.*

FDA Label Image

Figure 6 (Memantine And Donepezil Hydrochlorides 8)

FDA Label Image

Figure 7 (Memantine And Donepezil Hydrochlorides 9)

This text presents a chart showing the change in ADCS-ADL scores from baseline to 6 months for patients taking donepezil hydrochloride 10 mg/day compared to those on a placebo. The chart illustrates the mean values and standard errors for each group at 0, 3, and 6 months of drug treatment. The chart visually depicts the clinical improvement or decline in ADCS-ADL scores over the course of the study.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.